Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBT (2018 - 2025)

Addex Therapeutics' EBT history spans 8 years, with the latest figure at -$2.3 million for Q4 2025.

  • On a quarterly basis, EBT fell 68.91% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.3 million, a 48.36% decrease, with the full-year FY2025 number at -$8.3 million, down 47.27% from a year prior.
  • EBT came in at -$2.3 million for Q4 2025, down from -$2.0 million in the prior quarter.
  • The five-year high for EBT was $6.6 million in Q4 2022, with the low at -$7.5 million in Q2 2022.
  • Historically, EBT has averaged -$2.2 million across 5 years, with a median of -$1.9 million in 2024.
  • Biggest five-year swings in EBT: skyrocketed 237.36% in 2022 and later plummeted 177.79% in 2024.
  • Year by year, EBT stood at -$4.8 million in 2021, then soared by 237.36% to $6.6 million in 2022, then tumbled by 115.36% to -$1.0 million in 2023, then crashed by 34.16% to -$1.4 million in 2024, then crashed by 68.91% to -$2.3 million in 2025.
  • Business Quant data shows EBT for ADXN at -$2.3 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.4 million in Q2 2025.